Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
PrECOG, LLC.
Fundación GECP
Bristol-Myers Squibb
Instituto Nacional de Cancerologia de Mexico
Pfizer
Qianfoshan Hospital
Peking University Cancer Hospital & Institute
Aetion, Inc.
Aetion, Inc.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fox Chase Cancer Center
iOMEDICO AG
European Lung Cancer Working Party
Sungkyunkwan University
Daiichi Sankyo
Wake Forest University Health Sciences
Qilu Pharmaceutical Co., Ltd.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group